Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about DRD2/SNCA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | DRD2/SNCA |
| Key Genes/Proteins | CHR2/BDNF, CLOCK, CLOCK/ULK1, CRH, DRD2, FOXP3/TGFB1 |
| Related Diseases | neurodegeneration |
graph TD
DRD2_SNCA[DRD2/SNCA]
DRD2_SNCA -->|promoted: Smartphone-Detected Motor Variability Correction| neurodegeneration[neurodegeneration]
DRD2_SNCA -->|debate_co_mention| FOXP3_TGFB1[FOXP3/TGFB1]
DRD2_SNCA -->|debate_co_mention| neuroinflammation[neuroinflammation]
DRD2_SNCA -->|debate_co_mention| NR3C1[NR3C1]
DRD2_SNCA -->|debate_co_mention| NR3C1_CRH_TNFA[NR3C1/CRH/TNFA]
DRD2_SNCA -->|co_associated_with| PDGFRB_ANGPT1[PDGFRB/ANGPT1]
DRD2_SNCA -->|co_associated_with| PPARGC1A_PRKAA1[PPARGC1A/PRKAA1]
DRD2_SNCA -->|data_in| benchmark_ot_ad_answer_key_DRD[benchmark_ot_ad_answer_key:DRD2/SNCA]
CLOCK[CLOCK] -->|debate_co_mention| DRD2_SNCA
CLOCK_ULK1[CLOCK/ULK1] -->|debate_co_mention| DRD2_SNCA
CRH[CRH] -->|debate_co_mention| DRD2_SNCA
DRD2[DRD2] -->|debate_co_mention| DRD2_SNCA
CHR2_BDNF[CHR2/BDNF] -->|co_associated_with| DRD2_SNCA
benchmark_ot_ad_answer_key_DRD -->|data_in| DRD2_SNCA| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:DRD2/SNCA | data_in | dataset_row | 0.00 |
| neurodegeneration | associated_with | disease | 0.56 |
| FOXP3/TGFB1 | debate_co_mention | gene | 0.45 |
| neuroinflammation | debate_co_mention | process | 0.45 |
| NR3C1 | debate_co_mention | gene | 0.45 |
| NR3C1/CRH/TNFA | debate_co_mention | gene | 0.45 |
| NR3C1/CRH/TNFA | co_associated_with | gene | 0.40 |
| PDGFRB/ANGPT1 | co_associated_with | gene | 0.40 |
| FOXP3/TGFB1 | co_associated_with | gene | 0.40 |
| PPARGC1A/PRKAA1 | co_associated_with | gene | 0.40 |
| Source | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:DRD2/SNCA | data_in | dataset_row | 0.00 |
| CLOCK | debate_co_mention | gene | 0.45 |
| CLOCK/ULK1 | debate_co_mention | gene | 0.45 |
| CRH | debate_co_mention | gene | 0.45 |
| DRD2 | debate_co_mention | gene | 0.45 |
| CLOCK/ULK1 | co_associated_with | gene | 0.40 |
| CHR2/BDNF | co_associated_with | gene | 0.40 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Smartphone-Detected Motor Variability Correction | 0.742 | neurodegeneration | Digital biomarkers and AI-driven early d |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.756
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Computational Modeling of Alpha-Synuclein Propagation in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Alpha-Synuclein Seed Amplification Assay Validation | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Antiviral Therapy Trial for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Combination Therapy Sequencing in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Genetic Risk Modifiers in DLB Phenotype | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $7,500,000 |
| DLB Treatment Response Biomarkers — Predicting Cholinesterase Inhibito | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| Endocannabinoid System Dysfunction Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmaco [PMID:34106485] | Cacabelos R, Carrera I, Martínez O, Alej | Med Res Rev | 2021 | 1 |
| Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation [PMID:31120439] | Luo Z, Ahlers-Dannen KE, Spicer MM, Yang | JCI Insight | 2019 | 1 |
| Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant [PMID:31873106] | Yedlapudi D, Xu L, Luo D, Marsh GB, Todi | Sci Rep | 2019 | 1 |
| A systematic review and integrative approach to decode the common molecular link [PMID:28927418] | Guin D, Mishra MK, Talwar P, Rawat C, Ku | BMC Med Genomics | 2017 | 1 |
| The role of genetic factors in the occurrence of levodopa-induced motor complica [PMID:40632937] | ["Radojevi\u0107 B", "Milovanovi\u0107 A | Neurological research | 2026 | 0 |
| Reliability and Discriminant Ability of an Instrumented Timed Up and Go Test in [PMID:41921127] | ["Giardini M", "Arcolin I", "Arcobelli V | JMIR rehabilitation and assist | 2026 | 0 |
| Evaluating the Utility of Wearable Sensors for the Early Diagnosis of Parkinson [PMID:40690754] | ["Li H", "Zecca M", "Huang J"] | Journal of medical Internet re | 2025 | 0 |
| Effectiveness of instruments for assessing physical activity in adolescents: a s [PMID:41093309] | ["Kuanysh Z", "Vlassova A", "Seidakhmeto | Physical activity and nutritio | 2025 | 0 |
| Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Pa [PMID:41326766] | ["Gunter K", "Groenewald K", "Aubourg T" | NPJ digital medicine | 2025 | 0 |
| Wearable Sensor-Based Assessments for Remotely Screening Early-Stage Parkinson's [PMID:39275547] | ["Johnson S", "Kantartjis M", "Severson | Sensors (Basel, Switzerland) | 2024 | 0 |
| Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in S [PMID:38286627] | ["Arai M", "Suzuki E", "Kitamura S", "Ot | The Journal of neuroscience : | 2024 | 0 |
| Digital biomarkers in Parkinson's disease. [PMID:39181623] | ["Bougea A"] | Advances in clinical chemistry | 2024 | 0 |
| Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Rout [PMID:39098130] | ["Zhang Y", "Yu J", "Wen W"] | European journal of medicinal | 2024 | 0 |
| Wearable sensor-based gait analysis to discriminate early Parkinson's disease fr [PMID:36725698] | ["Lin S", "Gao C", "Li H", "Huang P", "L | Journal of neurology | 2023 | 0 |
| Associations between variants in levodopa metabolic pathway genes and levodopa-i [PMID:36813078] | ["Yan J", "Ge Y", "Wang P", "Li W", "Jin | Neuroscience letters | 2023 | 0 |
| Remote smartphone monitoring of Parkinson's disease and individual response to t [PMID:34373643] | ["Omberg L", "Chaibub Neto E", "Perumal | Nature biotechnology | 2022 | 0 |
| Wearable sensor device-based detection of decreased heart rate variability in Pa [PMID:35835890] | ["Suzuki M", "Nakamura T", "Hirayama M", | Journal of neural transmission | 2022 | 0 |
| In Parkinson's patient-derived dopamine neurons, the triplication of α-synuclein [PMID:34099060] | ["Lin M", "Mackie P", "Shaerzadeh F", "G | Acta neuropathologica communic | 2021 | 0 |
| Pharmacogenetics-Guided Advances in Antipsychotic Treatment. [PMID:34129738] | ["Islam F", "Men X", "Yoshida K", "Zai C | Clinical pharmacology and ther | 2021 | 0 |
| Patient, study thyself. [PMID:30470218] | ["Wicks P"] | BMC medicine | 2018 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning DRD2/SNCA in their description or question text
No additional research found